ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

[1]  Zhihua Liu,et al.  Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 , 2018, Proceedings of the National Academy of Sciences.

[2]  Bo Li,et al.  VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis , 2018, BMC Bioinformatics.

[3]  D. Tindall,et al.  Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer , 2018, Nucleic acids research.

[4]  M. Loda,et al.  Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing , 2017, Proceedings of the National Academy of Sciences.

[5]  K. Pienta,et al.  Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Sean R. Landman,et al.  Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer , 2016, Nature Communications.

[7]  K. Iczkowski,et al.  Analysis of Zinc-Exporters Expression in Prostate Cancer , 2016, Scientific Reports.

[8]  C. Drake,et al.  Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis , 2016, Prostate Cancer and Prostatic Diseases.

[9]  David S. K. Lu,et al.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[10]  Tao Liu,et al.  ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline , 2016, BMC Bioinformatics.

[11]  Shihua Sun,et al.  Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer , 2016, European urology.

[12]  A. Cecilia,et al.  Superporous Poly(ethylene glycol) Diacrylate Cryogel with a Defined Elastic Modulus for Prostate Cancer Cell Research. , 2016, Small.

[13]  Shenglin Mei,et al.  Modeling cis-regulation with a compendium of genome-wide histone H3K27ac profiles , 2016, Genome research.

[14]  J. Shendure,et al.  Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer , 2016, Nature Medicine.

[15]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[16]  S. Gambhir,et al.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. , 2015, Cancer research.

[17]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[18]  Michael D. Nyquist,et al.  Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies , 2015, Nucleic acids research.

[19]  M. Kattan,et al.  A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. , 2015, European urology.

[20]  D. Tindall,et al.  The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. , 2015, The Journal of urology.

[21]  B. Dai,et al.  Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer , 2015, Scientific Reports.

[22]  Jun S. Liu,et al.  MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.

[23]  D. Bryder,et al.  HIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia. , 2014, Blood.

[24]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[25]  F. Feng,et al.  Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy , 2014, International journal of radiation oncology, biology, physics.

[26]  Shihua Sun,et al.  Mechanisms of the androgen receptor splicing in prostate cancer cells , 2014, Oncogene.

[27]  Jindan Yu,et al.  Cooperativity and Equilibrium with FOXA1 Define the Androgen Receptor Transcriptional Program , 2014, Nature Communications.

[28]  Myles A Brown,et al.  Coregulator Control of Androgen Receptor Action by a Novel Nuclear Receptor-binding Motif* , 2014, The Journal of Biological Chemistry.

[29]  A. Visel,et al.  Rapid and Pervasive Changes in Genome-wide Enhancer Usage during Mammalian Development , 2013, Cell.

[30]  Anirban P. Mitra,et al.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.

[31]  Michael D. Nyquist,et al.  TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer , 2013, Proceedings of the National Academy of Sciences.

[32]  Jun Luo,et al.  Decoding the androgen receptor splice variants , 2013, Translational andrology and urology.

[33]  G. Jenster,et al.  Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer , 2013, International journal of cancer.

[34]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[35]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[36]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[37]  Takahiro Matsumoto,et al.  The androgen receptor in health and disease. , 2013, Annual review of physiology.

[38]  R. Vessella,et al.  Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration‐resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  P. Nelson,et al.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.

[40]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[41]  Arthur T. Johnson,et al.  Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring , 2012, Diagnostic Pathology.

[42]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[43]  W. V. van Cappellen,et al.  Stepwise androgen receptor dimerization , 2012, Journal of Cell Science.

[44]  O. Kallioniemi,et al.  Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer , 2011, The EMBO journal.

[45]  Liping Huang,et al.  A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model. , 2011, Cancer letters.

[46]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[47]  C. Glass,et al.  Reprogramming Transcription via Distinct Classes of Enhancers Functionally Defined by eRNA , 2011, Nature.

[48]  Ryan A. Flynn,et al.  A unique chromatin signature uncovers early developmental enhancers in humans , 2011, Nature.

[49]  F. Sotgia,et al.  HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells , 2010, Cell cycle.

[50]  P. Nelson,et al.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.

[51]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[52]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[53]  Clifford A. Meyer,et al.  Nucleosome Dynamics Define Transcriptional Enhancers , 2010, Nature Genetics.

[54]  Kristen Jepsen,et al.  Deconstructing repression: evolving models of co-repressor action , 2010, Nature Reviews Genetics.

[55]  Clifford A. Meyer,et al.  Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.

[56]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[57]  John Calvin Reed,et al.  Image Analysis Algorithms for Immunohistochemical Assessment of Cell Death Events and Fibrosis in Tissue Sections , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[58]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[59]  J. D. Benson,et al.  Single-vector inducible lentiviral RNAi system for oncology target validation , 2009, Cell cycle.

[60]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[61]  S. Nilsson,et al.  Testosterone surge: rationale for gonadotropin-releasing hormone blockers? , 2008, Urology.

[62]  A. Kibel,et al.  SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. , 2007, Human molecular genetics.

[63]  K. Pienta,et al.  A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.

[64]  D. Trono,et al.  Production and Titration of Lentiviral Vectors , 2007, Current protocols in human genetics.

[65]  Adriaan B. Houtsmuller,et al.  Compartmentalization of androgen receptor protein–protein interactions in living cells , 2007, The Journal of cell biology.

[66]  D. Trono,et al.  Production and titration of lentiviral vectors. , 2006, Current protocols in neuroscience.

[67]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  E. Wilson,et al.  Dependence of Selective Gene Activation on the Androgen Receptor NH2- and COOH-terminal Interaction* , 2002, The Journal of Biological Chemistry.

[69]  Christine Brun,et al.  In silico prediction of protein-protein interactions in human macrophages , 2001, BMC Research Notes.

[70]  Peter Scholz,et al.  Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor , 2000, The Journal of Biological Chemistry.

[71]  F. Claessens,et al.  The AF1 and AF2 Domains of the Androgen Receptor Interact with Distinct Regions of SRC1 , 1999, Molecular and Cellular Biology.

[72]  G. Coetzee,et al.  Multiple Signal Input and Output Domains of the 160-Kilodalton Nuclear Receptor Coactivator Proteins , 1999, Molecular and Cellular Biology.

[73]  J. Vonesch,et al.  Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators , 1998, The EMBO journal.

[74]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[75]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[76]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[77]  M. Luedeke,et al.  Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. , 2017, European urology.

[78]  B. Trock,et al.  Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. , 2016, European urology.

[79]  R. Houtman,et al.  Cofactor profiling of the glucocorticoid receptor from a cellular environment. , 2014, Methods in molecular biology.

[80]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[81]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[82]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[83]  N. Dubrawsky.  Cancer statistics , 2022 .

[84]  P. Stattin,et al.  Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival , 2011, PloS one.